ArticleEuropean journal of applied physiology2026
Intermittent exogenous ketosis does not reduce acute mountain sickness during early terrestrial high-altitude acclimatization.
Article in European journal of applied physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeIntermittent exogenous ketosis via ketone monoester (KE) ingestion has been shown to enhance physiological responses and reduce acute mountain sickness (AMS) symptoms during acute normobaric hypoxia. Its effects during early acclimatization to terrestrial high-altitude, however, remain unclear.
methodsThirty-four participants were randomised to an intermittent exogenous ketosis (IEK, n=17) or placebo (PLA, n=17) group and underwent a near sea level trial (295 m) without supplementation, followed by a four-day sojourn at 3375 m during which they received regular KE (IEK) or placebo (PLA) supplements. AMS symptoms, hematological markers, and resting ventilatory, cardiovascular, and cerebral tissue oxygenation responses were assessed each day upon waking, at midday, and before sleep throughout the exposure.
resultsKE consistently elevated circulating β-hydroxybutyrate post-ingestion (P<0.001), confirming intermittent exogenous ketosis in the IEK group. AMS incidence peaked at 25-35% after 8 h, however incidence and symptom severity were similar in IEK vs. PLA across the altitude exposure (P≥0.822). KE ingestion induced (keto)acidosis, resulting in augmented ventilatory response in IEK (P≤0.037), but failed to mitigate hypoxia-induced blood and cerebral deoxygenation relative to PLA (P≥0.234). KE ingestion increased daytime cardiac output and lowered morning blood pressure in IEK (P≤0.031), while it did not affect autonomic, eryrthropoietic, or redox responses compared to PLA (P≥0.099).
conclusionAlthough KE alters some physiological responses, it does not seem to importantly modulate AMS incidence and severity during early terrestrial altitude acclimatization.
Indexed as
Identifiers
42709151What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.